Posts tagged NYSE MKT:BTX
BioTime forms new AgeX unit on human aging

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology.

Read More
BioTime opens U.S. sites in dry AMD trial

BioTime (NYSE MKT:BTX) is expanding its ongoing Phase 1/2a clinical trial for OpRegen in the advanced dry form of AMD by naming the first two sites that will treat patients in the U.S.

Read More
BioTime closes $20.1-million offering

BioTime (NYSE MKT, TASE:BTX) has closed a public offering of 7,453,704 common shares, including 972,222 shares in connection with the exercise in full of an underwriters’ over allotment option, at a price of $2.70 a share for gross proceeds of about $20.1-million.

Read More
BioTime acquires rights to retinal disease assets

BioTime (NYSE MKT:BTX) has acquired global rights to ophthalmology-related intellectual property assets from the University of Pittsburgh’s Medical Center, via the school’s Innovation Institute.

Read More
Ladenburg starts BioTime at buy

Ladenburg Thalmann has initiated coverage of BioTime (NYSE MKT, TASE:BTX) with a “buy” rating and $6 price target. The stock closed at $3.59 on Thursday.

“We view BioTime as roughly halfway through a restructuring designed to unlock shareholder value through separation of non-core assets and accelerated development of the company's cell therapy programs in ophthalmetry, aesthetics and orthopedics,” writes analyst Kevin DeGeeter.

Read More